A seminal work of Loi et al. indeed demonstrated that, in ER+ HER2− breast cancer, PIK3CA mutation surprisingly did not always result in elevated downstream signaling, and correlated with relatively low mTORC1 signaling [31,32]. This evidence concerns the gene ESR1 and breast cancer.